Stockscreener 앱 받기
0.404
10.22%
-0.046
Allovir Inc 주식(ALVR)의 최신 뉴스
AlloVir appoints new CEO following leadership shakeup By Investing.com - Investing.com South Africa
AlloVir appoints new CEO following leadership shakeup - Investing.com India
AlloVir CEO Departs, CFO Steps In - MarketWatch
AlloVir Appoints Vikas Sinha as New CEO - TipRanks
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - The Eastern Progress Online
Allovir stock touches 52-week low at $0.47 amid market challenges - Investing.com
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
AlloVir (NASDAQ:ALVR) Stock Price Down 1.2%What's Next? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AlloVir, Inc. (NasdaqALVR), EMCORE Corporation (NasdaqEMKR), Staffing 360 Solutions, Inc. (NasdaqSTAF), Adams Resources & Energy, Inc. (NYSE American - GlobeNewswire Inc.
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders - GlobeNewswire Inc.
Influenza Pipeline Insights 2024: Therapies, Clinical Trials, - openPR
Allovir stock hits 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
Allovir stock hits 52-week low at $0.5 amid market challenges - Investing.com Nigeria
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - Scrip
Allovir stock plunges to 52-week low, touches $0.51 By Investing.com - Investing.com Canada
Allovir stock plunges to 52-week low, touches $0.51 - Investing.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of INSI, LBRDA, ROIC and ALVR - The Malaysian Reserve
Finansavisen - Finansavisen
AlloVir falls after all-stock merger deal with Kalaris - MSN
AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com
AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau
Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India
$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire
AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology
AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs
$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire
ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Items Tagged with 'TH-103' - BioWorld Online
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury
Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online
Allovir sees a new direction with Kalaris merger - BioWorld Online
SEC Form 425 filed by AlloVir Inc. - Quantisnow
Kalaris to go public via reverse merger with AlloVir - BioPharma Dive
AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
2.88%
2.65%
자본화:
|
볼륨(24시간):